EP3805222A3 - 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onderivate und salze davon und deren verwendung in der therapie - Google Patents

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onderivate und salze davon und deren verwendung in der therapie Download PDF

Info

Publication number
EP3805222A3
EP3805222A3 EP20198062.0A EP20198062A EP3805222A3 EP 3805222 A3 EP3805222 A3 EP 3805222A3 EP 20198062 A EP20198062 A EP 20198062A EP 3805222 A3 EP3805222 A3 EP 3805222A3
Authority
EP
European Patent Office
Prior art keywords
benzyl
alkyl
hexahydroimidazo
pyrido
methylbenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20198062.0A
Other languages
English (en)
French (fr)
Other versions
EP3805222B1 (de
EP3805222A2 (de
Inventor
Martin Stogniew
Joshua E. Allen
Richard S. Pottorf
Bhaskara Rao Nallaganchu
Gary L. Olson
Yanjun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoceutics Inc
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HRP20250250TT priority Critical patent/HRP20250250T1/hr
Priority to EP24210662.3A priority patent/EP4512483A3/de
Priority to SI201631886T priority patent/SI3805222T1/sl
Priority to RS20250206A priority patent/RS66551B1/sr
Priority to MA55402A priority patent/MA55402B1/fr
Priority to EP25152627.3A priority patent/EP4516359A3/de
Priority to SM20250087T priority patent/SMT202500087T1/it
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of EP3805222A2 publication Critical patent/EP3805222A2/de
Publication of EP3805222A3 publication Critical patent/EP3805222A3/de
Application granted granted Critical
Publication of EP3805222B1 publication Critical patent/EP3805222B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5756—Prolactin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
EP20198062.0A 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onderivate, deren salze und deren verwendung in der therapie Active EP3805222B1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP24210662.3A EP4512483A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie
SI201631886T SI3805222T1 (sl) 2015-01-30 2016-01-29 Derivati 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(1H)-ona, njihove soli in njihova uporaba v terapiji
RS20250206A RS66551B1 (sr) 2015-01-30 2016-01-29 Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
MA55402A MA55402B1 (fr) 2015-01-30 2016-01-29 Dérivés de 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, leurs sels et leur utilisation en thérapie
HRP20250250TT HRP20250250T1 (hr) 2015-01-30 2016-01-29 Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
SM20250087T SMT202500087T1 (it) 2015-01-30 2016-01-29 Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
EP25152627.3A EP4516359A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562109737P 2015-01-30 2015-01-30
US201562148844P 2015-04-17 2015-04-17
US201562233757P 2015-09-28 2015-09-28
EP16744237.5A EP3250208B1 (de) 2015-01-30 2016-01-29 7-benzyl-4-(4-(trifluoromethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on und salze davon und deren verwendung in der therapie
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP16744237.5A Division EP3250208B1 (de) 2015-01-30 2016-01-29 7-benzyl-4-(4-(trifluoromethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on und salze davon und deren verwendung in der therapie

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP25152627.3A Division EP4516359A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie
EP24210662.3A Division EP4512483A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie

Publications (3)

Publication Number Publication Date
EP3805222A2 EP3805222A2 (de) 2021-04-14
EP3805222A3 true EP3805222A3 (de) 2021-06-30
EP3805222B1 EP3805222B1 (de) 2024-12-04

Family

ID=56544438

Family Applications (4)

Application Number Title Priority Date Filing Date
EP16744237.5A Active EP3250208B1 (de) 2015-01-30 2016-01-29 7-benzyl-4-(4-(trifluoromethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on und salze davon und deren verwendung in der therapie
EP20198062.0A Active EP3805222B1 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onderivate, deren salze und deren verwendung in der therapie
EP25152627.3A Pending EP4516359A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie
EP24210662.3A Pending EP4512483A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16744237.5A Active EP3250208B1 (de) 2015-01-30 2016-01-29 7-benzyl-4-(4-(trifluoromethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on und salze davon und deren verwendung in der therapie

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP25152627.3A Pending EP4516359A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie
EP24210662.3A Pending EP4512483A3 (de) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a pyrido[3,4-e!pyrimidin-5(1h)-on, analoga davon und salze davon und verfahren zu deren verwendung in der therapie

Country Status (27)

Country Link
US (6) US9845324B2 (de)
EP (4) EP3250208B1 (de)
JP (4) JP6802172B2 (de)
KR (3) KR102856422B1 (de)
CN (2) CN107427516B8 (de)
AU (4) AU2016211243B2 (de)
BR (1) BR112017016487B1 (de)
CA (3) CA2975476C (de)
CY (1) CY1123616T1 (de)
DK (2) DK3250208T3 (de)
EA (1) EA037552B1 (de)
ES (2) ES2839401T3 (de)
FI (1) FI3805222T3 (de)
HR (2) HRP20250250T1 (de)
HU (2) HUE052821T2 (de)
IL (5) IL312936A (de)
LT (2) LT3805222T (de)
MA (2) MA41434B1 (de)
MD (2) MD3250208T2 (de)
MX (3) MX2021001096A (de)
PL (2) PL3250208T3 (de)
PT (2) PT3250208T (de)
RS (2) RS61243B1 (de)
SG (2) SG11201706062TA (de)
SI (2) SI3805222T1 (de)
SM (2) SMT202000696T1 (de)
WO (1) WO2016123571A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052821T2 (hu) 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
RS66519B1 (sr) * 2016-01-29 2025-03-31 Oncoceutics Inc Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
IL297201A (en) 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3033667A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US20200129596A1 (en) * 2017-03-13 2020-04-30 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT
EP3589745A1 (de) * 2018-04-11 2020-01-08 Chemestmed Ltd. Verfahren zur modulation der rna-methylierung
TWI910104B (zh) 2019-03-26 2026-01-01 日商富士軟片股份有限公司 對屬於ｙｔｈｄｃ家族之蛋白質的表現或功能之抑制劑之用途、及篩選抑制ｂ型肝炎病毒蛋白質產生的物質之方法
BR112022015011A2 (pt) * 2020-01-29 2022-09-20 Corcept Therapeutics Inc Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical
EP4192467A1 (de) * 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthese von neuen imipridonderivaten und ihre beurteilung auf ihre antikrebswirkung
EP4223876A4 (de) 2020-09-30 2025-12-10 Fujifilm Corp Doppelsträngige rna zur hemmung der produktion von hepatitis-b-virusprotein und pharmazeutische zusammensetzung
KR20230118855A (ko) * 2020-11-13 2023-08-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 IRE1α 억제제 및 이의 용도
CN113100233B (zh) * 2021-04-19 2022-02-08 中国农业科学院植物保护研究所 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
EP4698146A1 (de) * 2023-04-20 2026-02-25 Institut Gustave-Roussy Flüssige und feste zusammensetzungen von imipridonderivaten
CN119306718A (zh) * 2023-07-11 2025-01-14 中科中山药物创新研究院 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
WO2025250553A1 (en) * 2024-05-28 2025-12-04 Chimerix, Inc. Solid state forms of imipridone derivative
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung
CN119198986B (zh) * 2024-11-28 2025-03-11 淄博高新技术产业开发区生物医药研究院 化药中n-亚硝基双氯芬酸基因毒杂质含量的分析方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335048A1 (en) * 2013-03-13 2014-11-13 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy
WO2015153468A1 (en) * 2014-03-31 2015-10-08 The Scripps Research Institute Pharmacophore for trail induction

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
AU2003253186A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070026402A1 (en) 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US20080221135A1 (en) 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
WO2010033315A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
CA2746129A1 (en) 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals
US9724337B2 (en) 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
WO2011144622A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh 1h - imidazo [4, 5 - c] quinolines
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
EP2694678A2 (de) * 2011-04-04 2014-02-12 Netherland Cancer Institute Verfahren und zusammensetzungen zur vorhersage der resistenz gegenüber einer antikrebsbehandlung
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
EP3679934B1 (de) * 2011-04-29 2024-06-05 The Penn State Research Foundation Kleinmolekülige trail-gen-induzierung durch normale und tumor-zellen als antikrebstherapie
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
SI2968294T1 (sl) * 2013-03-13 2019-08-30 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo(1,2-A)pirido (4,3-D)pirimidin-5(3H)-on za uporabo pri zdravljenju raka
KR102318238B1 (ko) * 2013-11-15 2021-10-26 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
KR20150114239A (ko) * 2014-04-01 2015-10-12 제일모직주식회사 내열성 및 착색성이 향상된 열가소성 수지 조성물
HUE052821T2 (hu) * 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335048A1 (en) * 2013-03-13 2014-11-13 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy
WO2015153468A1 (en) * 2014-03-31 2015-10-08 The Scripps Research Institute Pharmacophore for trail induction

Also Published As

Publication number Publication date
SMT202500087T1 (it) 2025-03-12
RS66551B1 (sr) 2025-03-31
RS61243B1 (sr) 2021-01-29
KR102618971B1 (ko) 2023-12-27
AU2024203421A1 (en) 2024-06-13
EA201791727A1 (ru) 2018-01-31
JP2025186367A (ja) 2025-12-23
EP4516359A3 (de) 2025-04-23
SG10201803508WA (en) 2018-05-30
CA3209515A1 (en) 2016-08-04
NZ733994A (en) 2024-04-26
JP2021050209A (ja) 2021-04-01
CN113149985A (zh) 2021-07-23
MA41434B1 (fr) 2021-03-31
US20190194201A1 (en) 2019-06-27
AU2020286168B2 (en) 2022-06-09
US20220017519A1 (en) 2022-01-20
CY1123616T1 (el) 2022-03-24
ES2839401T3 (es) 2021-07-05
IL274135A (en) 2020-06-30
US10266533B2 (en) 2019-04-23
US20180072729A1 (en) 2018-03-15
CA2975476A1 (en) 2016-08-04
AU2022228096A1 (en) 2022-09-29
SI3805222T1 (sl) 2025-04-30
CA2975476C (en) 2023-10-03
MX379425B (es) 2025-03-11
LT3805222T (lt) 2025-02-10
IL288525A (en) 2022-01-01
EP3250208A1 (de) 2017-12-06
IL295286A (en) 2022-10-01
MX2021001096A (es) 2023-01-17
HRP20201949T1 (hr) 2021-01-22
HRP20250250T1 (hr) 2025-03-28
HUE070309T2 (hu) 2025-05-28
EP4512483A3 (de) 2025-04-23
KR20250134216A (ko) 2025-09-09
EP3250208A4 (de) 2018-10-03
MA41434A (fr) 2017-12-06
SMT202000696T1 (it) 2021-01-05
AU2020286168B8 (en) 2022-09-22
IL295286B1 (en) 2024-06-01
JP2024160257A (ja) 2024-11-13
MD3805222T2 (ro) 2025-04-30
CN107427516B8 (zh) 2021-04-09
JP2018503663A (ja) 2018-02-08
BR112017016487B1 (pt) 2023-11-07
AU2016211243A1 (en) 2017-08-10
IL295286B2 (en) 2024-10-01
PT3250208T (pt) 2021-01-06
PL3805222T3 (pl) 2025-04-07
NZ772369A (en) 2024-07-05
NZ772080A (en) 2024-07-05
US20170096431A1 (en) 2017-04-06
IL253689B (en) 2020-05-31
FI3805222T3 (fi) 2025-01-22
IL253689A0 (en) 2017-09-28
ES3009132T3 (en) 2025-03-26
US9845324B2 (en) 2017-12-19
EP3805222B1 (de) 2024-12-04
CN113149985B (zh) 2025-01-28
US11976068B2 (en) 2024-05-07
KR102856422B1 (ko) 2025-09-04
CN107427516B (zh) 2021-02-26
MD3250208T2 (ro) 2021-02-28
MX2017009841A (es) 2018-02-09
SI3250208T1 (sl) 2021-01-29
JP7579684B2 (ja) 2024-11-08
IL288525B (en) 2022-09-01
EP4512483A2 (de) 2025-02-26
PL3250208T3 (pl) 2021-04-06
LT3250208T (lt) 2021-01-25
MX2023000782A (es) 2023-02-14
JP6802172B2 (ja) 2020-12-16
AU2024203421B2 (en) 2026-03-12
US20240270746A1 (en) 2024-08-15
CA3209519A1 (en) 2016-08-04
SG11201706062TA (en) 2017-08-30
MA55402A (fr) 2022-02-02
AU2016211243B2 (en) 2020-09-10
DK3805222T3 (da) 2025-01-06
IL312936A (en) 2024-07-01
MA55402B1 (fr) 2025-02-28
WO2016123571A1 (en) 2016-08-04
AU2020286168A1 (en) 2021-01-07
EA037552B1 (ru) 2021-04-13
IL274135B (en) 2022-01-01
EP3250208B1 (de) 2020-09-30
EP3805222A2 (de) 2021-04-14
HUE052821T2 (hu) 2021-05-28
PT3805222T (pt) 2025-03-10
KR20240005186A (ko) 2024-01-11
US20250109133A1 (en) 2025-04-03
BR112017016487A2 (pt) 2018-04-10
CN107427516A (zh) 2017-12-01
DK3250208T3 (da) 2021-01-04
EP4516359A2 (de) 2025-03-05
KR20170109583A (ko) 2017-09-29

Similar Documents

Publication Publication Date Title
EP3805222A3 (de) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onderivate und salze davon und deren verwendung in der therapie
NZ751509A (en) Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
CY1126663T1 (el) Παραγωγα 2,3-διυδρο-1η-πυρρολο[3,4-c]πυριδιν-1- ονης ως αναστολεις της ηρκ1 για τη θεραπεια καρκινου
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
PH12019500930A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
MX388140B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CY1124832T1 (el) 7-βενζυλο-4-(2-μεθυλοβενζυλο)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1 η)-ονη, τα αλατα της και οι μεθοδοι χρησης τους σε συνδυαστικη θεραπεια
SG11201906579UA (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201491456A1 (ru) Соединения-ингибиторы raf
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EP3744723A4 (de) Substituierte makrocyclische pyrazolo[1,5-a]pyrimidinverbindung
CL2021000276A1 (es) Polimorfo cristalino del clorhidrato de 8-bromo-2-(1-metilpiperidin-4-ilamin)-4-(4-fenoxifenilamin)pirido[4,3-d]pirimidin-5(6h)-ona y método para prepararlo.
EP4403560A3 (de) Makrozyklische verbindungen und verwendungen davon
EP3568400C0 (de) Verfahren zur herstellung von 3-substituiertem 5-amino-6h-thiazolo[4,5-d]pyrimidin-2,7-dion verbindungen
WO2015112705A3 (en) Therapeutic combinations for treating cancer
PH12019500478A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
MX2017009597A (es) Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100.
IL278935B2 (en) Piazolo[e-3,4]pyrimidine compounds are being modified for use in cancer treatment
EP3903788A4 (de) Makrocyclische pyrazolo[1,5-a]pyrimidinverbindung
RU2014120150A (ru) Замещенные пиразоло[1,5-а]пиримидиновые соединения как ингибиторы трк киназы
WO2017040980A3 (en) Quinoxalinyl-piperazinamide methods of use
GEP20197016B (en) 7-(morpholinyl)-2-(n-piperazinyl)methyl thieno[2,3-c]pyridine derivatives as anticancer drugs

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20250250T

Country of ref document: HR

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3250208

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/14 20060101AFI20210525BHEP

Ipc: A61K 31/519 20060101ALI20210525BHEP

Ipc: A61P 35/00 20060101ALI20210525BHEP

Ipc: A61K 31/337 20060101ALI20210525BHEP

Ipc: A61K 45/06 20060101ALI20210525BHEP

Ipc: A61P 9/02 20060101ALI20210525BHEP

Ipc: A61P 13/08 20060101ALI20210525BHEP

Ipc: A61P 15/00 20060101ALI20210525BHEP

Ipc: A61P 21/00 20060101ALI20210525BHEP

Ipc: A61P 25/00 20060101ALI20210525BHEP

Ipc: A61P 25/18 20060101ALI20210525BHEP

Ipc: A61P 25/22 20060101ALI20210525BHEP

Ipc: A61P 31/14 20060101ALI20210525BHEP

Ipc: A61P 31/16 20060101ALI20210525BHEP

Ipc: A61P 31/18 20060101ALI20210525BHEP

Ipc: A61P 31/20 20060101ALI20210525BHEP

Ipc: A61P 31/22 20060101ALI20210525BHEP

Ipc: A61P 35/02 20060101ALI20210525BHEP

Ipc: A61P 35/04 20060101ALI20210525BHEP

Ipc: A61P 43/00 20060101ALI20210525BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050602

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211223

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20211223

Extension state: MA

Effective date: 20211223

RAX Requested extension states of the european patent have changed

Extension state: ME

Payment date: 20211223

Extension state: BA

Payment date: 20211223

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221202

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230606

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240702

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 3250208

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016090551

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20250103

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 55402

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3805222

Country of ref document: PT

Date of ref document: 20250310

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20250228

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20250250T

Country of ref document: HR

Payment date: 20250304

Year of fee payment: 10

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3009132

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20250326

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20250250

Country of ref document: HR

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20250115

Year of fee payment: 10

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 46022

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20250400436

Country of ref document: GR

Effective date: 20250409

REG Reference to a national code

Ref country code: MD

Ref legal event code: VAGR

Ref document number: 3805222

Country of ref document: MD

Date of ref document: 20250430

Kind code of ref document: T2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20250120

Year of fee payment: 10

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E070309

Country of ref document: HU

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E025006

Country of ref document: EE

Effective date: 20250303

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20250110

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016090551

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: L10

Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251015

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20250203

Year of fee payment: 10

26N No opposition filed

Effective date: 20250905

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20250218

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20251231

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20251230

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260201

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20250250

Country of ref document: HR

Payment date: 20260113

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20260127

Year of fee payment: 11

Ref country code: NL

Payment date: 20260126

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20260109

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1748067

Country of ref document: AT

Kind code of ref document: T

Effective date: 20241204

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20260112

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20260127

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20251231

Year of fee payment: 11

Ref country code: GB

Payment date: 20260127

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20260105

Year of fee payment: 11

Ref country code: ES

Payment date: 20260202

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20260128

Year of fee payment: 11

Ref country code: NO

Payment date: 20260128

Year of fee payment: 11

Ref country code: DK

Payment date: 20260126

Year of fee payment: 11

Ref country code: IE

Payment date: 20260127

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HR

Payment date: 20260113

Year of fee payment: 11

Ref country code: AT

Payment date: 20260128

Year of fee payment: 11

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20260120

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20260126

Year of fee payment: 11

Ref country code: BE

Payment date: 20260127

Year of fee payment: 11

Ref country code: RO

Payment date: 20260113

Year of fee payment: 11

Ref country code: IT

Payment date: 20260121

Year of fee payment: 11

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MA

Payment date: 20260129

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20260105

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260126

Year of fee payment: 11

Ref country code: IS

Payment date: 20260120

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20260116

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20260201

Year of fee payment: 11

Ref country code: CZ

Payment date: 20260108

Year of fee payment: 11

Ref country code: PT

Payment date: 20260112

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20260127

Year of fee payment: 11

Ref country code: PL

Payment date: 20260102

Year of fee payment: 11

Ref country code: CY

Payment date: 20260109

Year of fee payment: 11

Ref country code: MT

Payment date: 20260108

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20260112

Year of fee payment: 11

Ref country code: SK

Payment date: 20260102

Year of fee payment: 11